Marc Silver, MD
Clinical Cardiac Electrophysiology · Raleigh, NCNPI 1902802945
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $85,000 of the $112,536 with a category attached, or 75.5%. Daxor Corporation accounts for 80.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $86,512 and has fallen 99.4% since, to $512 in 2025.
Across 164 payments — averaging $686.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daxor Corporation$90K
- Medtronic$20K
- Irhythm Technologies, Inc.$370
- Boston Scientific$287
- Pfizer$252
- Novartis$176
- plus $1K from 21 others
Across 160 payments — averaging $2728.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$433K
- AstraZeneca$3K
- Cvrx, Inc.$1K
What the payments were for
- Consulting fees$85,00076%
- Speaking & faculty fees$15,40014%
- Travel & lodging$8,8088%
- Food & beverage$3,3283%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daxor Corporation | 29 | $90,025 |
| Medtronic(2 entities) | 27 | $20,319 |
| Irhythm Technologies, Inc. | 10 | $370 |
| Boston Scientific | 8 | $287 |
| Pfizer | 16 | $252 |
| Novartis | 11 | $176 |
| AstraZeneca | 9 | $138 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $136 |
| E.r. Squibb & Sons, L.L.C. | 7 | $99 |
| Philips North America LLC | 5 | $93 |
| Heartflow, Inc. | 4 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $72 |
| Johnson & Johnson(2 entities) | 3 | $65 |
| Abbott | 2 | $61 |
| Merck | 4 | $59 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Braemar Manufacturing, LLC | 1 | $46 |
| Baxter Healthcare | 2 | $40 |
| Edwards Lifesciences | 1 | $28 |
| Atricure, Inc. | 1 | $26 |
| Nuwellis, Inc. | 1 | $23 |
| Davol Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Amgen | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BVA-100$89,957
- Arctic Front$4,651
- Claria MRI$145
- Visia AF$102
How this compares
$112,536 in reported general payments places this provider in the 85th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.
See all clinical cardiac electrophysiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 726 | $789,328 |
| EntrestoSacubitril/Valsartan | 148 | $163,414 |
| XareltoRivaroxaban | 97 | $96,564 |
| Repatha SureclickEvolocumab | 65 | $53,807 |
| FarxigaDapagliflozin Propanediol | 35 | $35,990 |
| JardianceEmpagliflozin | 20 | $16,485 |
| Praluent PenAlirocumab | 12 | $10,766 |
| Metoprolol Succinate | 445 | $5,769 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $5,512 |
| Flecainide Acetate | 123 | $4,620 |
| Dofetilide | 24 | $3,279 |
| Atorvastatin Calcium | 372 | $3,055 |
| Carvedilol | 325 | $2,400 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 120 | $2,070 |
| Losartan Potassium | 239 | $2,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $252 | $789,328726 claims |
| NovartisEntresto | $176 | $163,414148 claims |
| Johnson & JohnsonXarelto | $65 | $96,56497 claims |
| AstraZenecaFarxiga | $138 | $35,99035 claims |
| Boehringer IngelheimJardiance | $17 | $16,48520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.
Other clinical cardiac electrophysiology in Raleigh
- Kevin ManochaRaleigh$146K
- Sidharth ShahRaleigh$55K
- Joseph BumgarnerRaleigh$53K
- Ashish PatelRaleigh$15K
- Michael ManogueAsheville$230K
- Daniel FriedmanDurham$196K
- James AllredGreensboro$184K
- John RhynerAsheville$168K
- Gregory HarrisGreenville$164K
- John CatanzaroGreenville$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.